• Сучасна стратегія лікування виразкового коліту у дітей 
До змісту

Сучасна стратегія лікування виразкового коліту у дітей 

SOVREMENNAYA PEDIATRIYA.2015.5(69):81-87; doi 10.15574/SP.2015.69.81 

Сучасна стратегія лікування виразкового коліту у дітей 

Березенко В. С., Ткалик О. М., Диба М. Б., Михайлюк Х. З.

ДУ «Інститут педіатрії, акушерства та гінекології НАМН України», м. Київ 

У статті показано сучасну стратегію лікування виразкового коліту у дітей відповідно до консенсусу ECCO і ESPGHAN (2012). Наведено покроковий алгоритм терапії виразкового коліту згідно з рекомендаціями NICE (National Institute for Health and Clinical Excellence, UK, 2013). 

Ключові слова: виразковий коліт, діти, лікування, ECCO, ESPGHAN, NICE. 



1. Клиническая диетология детского возраста. Под ред. ТЭ Боровик, КС Ладодо. Москва. 2008: 608.

2. Baudet A, Colombel JF, Cortot A et al. 2010. A fulminant colitis index greater or equal to 8 is not predictive of colectomy risk in infliximab-treated moderate-to-severe ulcerative colitis attacks. Gastroenterologie Clinique Et Biologique. 34(11): 612—617. http://dx.doi.org/10.1016/j.gcb.2010.07.013; PMid:20832218

3. Khan KJ, Ullman TA, Ford AC et al. 2011. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 106: 661—673. http://dx.doi.org/10.1038/ajg.2011.64http://dx.doi.org/10.1038/ajg.2011.131http://dx.doi.org/10.1038/ajg.2011.72; PMid:21407187

4. Turner D, Hyams J, Markowitz J et al. 2009. Appraisal of the Pediatric Ulcerative Colitis Activity Index (PUCAI). Inflamm Bowel Dis. 15: 1218—1223. http://dx.doi.org/10.1002/ibd.20867; PMid:19161178

5. Timmer A, McDonald JWD, Tsoulis DJ et al. 2012. Azathioprine and 6_mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews. —— Issue 9: CD000478. http://dx.doi.org/10.1002/14651858.CD000478.pub3.

6. Biancone L, Gionchetti P, Blanco GDV et al. 2007. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: A multicenter, randomized, doubleblind study. Digestive and Liver Disease. 39(4): 329—337. http://dx.doi.org/10.1016/j.dld.2007.01.012; PMid:17347061

7. Burisch J, Munkholm P. 2013. Inflammatory bowel disease epidemiology. Current Opinionin Gastroenterology. 29(4): 357—362. [PubMed] http://dx.doi.org/10.1097/MOG.0b013e32836229fb; PMid:23695429

8. Chande N, MacDonald JK, McDonald JWD. 2007. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews. Issue 4:CD006618. http://dx.doi.org/10.1002/14651858.CD006618.pub2

9. Branche J, Cortot A, Bourreille A et al. 2009. Cyclosporine treatment of steroid_refractory ulcerative colitis during pregnancy. Inflammatory Bowel Diseases. 15(7): 1044—1048. http://dx.doi.org/10.1002/ibd.20858; PMid:19137604

10. Halmos EP, Gibson PR. 2012. Dietary management of IBD-insights and advice Nature Reviews. Gastroenterology & Hepatology: 133—146 (2015) http://dx.doi.org/10.1038/nrgastro.2015.11; PMid:25645969

11. Van Limbergen J, Russell RK, Drummond HE et al. 2008. Difinition of phenotypic caracteristics of children-onset inflammatory bowel disease. Gastroenterology. 57: 331—385.

12. Van Limbergen J, Russell RK, Drummond HE et al. 2008. Difinition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 135: 1114-1122. http://dx.doi.org/10.1053/j.gastro.2008.06.081; PMid:18725221

13. Miele E, Pascarella F, Giannetti E et al. 2009. Effect of a probiotic preparation (VSL-3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 104: 437—443. http://dx.doi.org/10.1038/ajg.2008.118; PMid:19174792

14. Heyman MB, Kierkus J, Spenard J et al. 2010. Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents. Inflamm Bowel Dis. 16: 19. http://dx.doi.org/10.1002/ibd.21256; PMid:20848454 PMCid:PMC3252049

15. Ford AC, Achkar JP, Khan KJ et al. 2011. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 106: 601—616. http://dx.doi.org/10.1038/ajg.2011.67http://dx.doi.org/10.1038/ajg.2011.71

16. Khan KJ, Dubinsky MC, Ford AC et al. 2011. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 106: 630—642. http://dx.doi.org/10.1038/ajg.2011.64http://dx.doi.org/10.1038/ajg.2011.131http://dx.doi.org/10.1038/ajg.2011.72

17. Zocco MA, dal Verme LZ, Cremonini F et al. 2006. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 23: 1567—1574. http://dx.doi.org/10.1111/j.1365-2036.2006.02927.x; PMid:16696804

18. Ford AC, Khan KJ, Sandborn WJ et al. 2012. Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis. Clin Gastroenterol Hepatol. 10: 513—519. http://dx.doi.org/10.1016/j.cgh.2011.10.043; PMid:22083024

19. Benchimol EI, Fortinsky KJ, Gozdyra P et al. 2011. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis. 17: 423—39. http://dx.doi.org/10.1002/ibd.21349; PMid:20564651

20. Rahier JF, Ben-Horin S, Chowers Y, Crohns J et al. 2009. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. Colitis. 3: 47—91. http://dx.doi.org/10.1016/j.crohns.2009.02.010; PMid:21172250

21. Glick SR, Carvalho RS. 2011. Inflammatory bowel disease. Pediatr Rev. 32: 14—24. http://dx.doi.org/10.1542/pir.32-1-14; PMid:21196502

22. Guslandi M, Giollo P, Testoni PA. 2003. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol. 15: 697—698. http://dx.doi.org/10.1097/00042737-200306000-00017; PMid:12840682

23. Harris MS, Lichtenstein GR. 2011. Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 33: 996—1009. http://dx.doi.org/10.1111/j.1365-2036.2011.04619.x; PMid:21385194

24. Jakobovits SL, Jewell DP, Travis SP. 2007. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. Aliment Pharmacol Ther. 25: 1055—1060. http://dx.doi.org/10.1111/j.1365-2036.2007.03300.x; PMid:17439506

25. Lev-Tzion R, Turner D. 2012. Is pediatric IBD treatment different than in adults? Minerva Gastroenterol Dietol. 58: 137—150. PMid:22643596

26. Lichtenstein GR, Kamm MA. 2008. Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis-methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa. Aliment Pharmacol Ther. 28: 663—673. http://dx.doi.org/10.1111/j.1365-2036.2008.03751.x; PMid:18532992

27. Piodi LP, Ulivieri FM, Cermesoni L et al. 2004. Long-term intermittent treatment with low-dose 5-Aminosalicylic enemas for remission maintenance in ulcerative colitis. Scandinavian Journal of Gastroenterology. 39: 154—157. http://dx.doi.org/10.1080/00365520310008133; PMid:15000277

28. Turner D, Levine A, Escher JC et al. 2012. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based Consensus guidelines. J Pediatr Gastroenterol Nutr. 55(3): 340—61. http://dx.doi.org/10.1097/MPG.0b013e3182662233; PMid:22773060

29. National Institute for Health and Clinical Excellence. Infliximab for acute exacerbations of ulcerative colitis (TA163). London, National Institute for Health and Clinical Excellence (NICE). 2008. http://guidance.nice.org.uk/TA163.

30. Ohkusa T, Kato K, Terao S et al. 2010. Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol. 105: 1820—1829. http://dx.doi.org/10.1038/ajg.2010.84; PMid:20216533

31. Aloi M, D'Arcangelo G, Pofi F et al. 2013. Presenting features and disease course of pediatric ulcerative colitis. J Crohns Colitis. 7: 509—515 (1).

32. Henker J, Muller S, Laass MW et al. 2008. Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study. Am J Gastroenterol. 46: 874—875. http://dx.doi.org/10.1055/s-2008-1027463

33. Kamm MA, Lichtenstein GR, Sandborn WJ et al. 2008. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut. 57(7): 893—902. http://dx.doi.org/10.1136/gut.2007.138248; PMid:18272546 PMCid:PMC2564831

34. Razack R, Seidner DL. 2007. Nutrition in inflammatory bowel disease. Curr Opin Gastroenterol. 23: 400—405. http://dx.doi.org/10.1097/MOG.0b013e3281ddb2a3; PMid:17545776

35. Regueiro M, Curtis J, Plevy S. 2006. Infliximab for hospitalized patients with severe ulcerative colitis. J Clin Gastroenterol. 40: 476—81. http://dx.doi.org/10.1097/00004836-200607000-00004; PMid:16825928

36. Turner D, Walsh CM, Steinhart AH et al. 2007. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 5: 103—110. http://dx.doi.org/10.1016/j.cgh.2006.09.033; PMid:17142106

37. Turner D, Mack D, Leleiko N et al. 2010. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology. 138: 2282—2291. http://dx.doi.org/10.1016/S0016-5085(10)60132-1http://dx.doi.org/10.1053/j.gastro.2010.02.047; PMid:20193683

38. Aceituno M, Garcia-Planella E, Heredia C et al. 2008. Steroid-refractory ulcerative colitis: predictive factors of response to cyclosporine and validation in an independent cohort. Inflammatory Bowel Diseases. 14(3): 347—352. http://dx.doi.org/10.1002/ibd.20322; PMid:18050296

39. Sutherland L, Macdonald JK. 2006. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. CD000543. http://dx.doi.org/10.1002/14651858.cd000543.pub2

40. Yasukawa K, Tokuda H, Tun X et al. 2012. The detrimental effect of nitric oxide on tissue is associated with inflammatory events in the vascular endothelium and neutrophils in mice with dextran sodium sulfate-induced colitis. Free Radic Res. 46: 1427—1436. http://dx.doi.org/10.3109/10715762.2012.732698; PMid:22998024

41. Malaty HM, Mehta S, Abraham B et al. 2013. The natural course of inflammatory bowel disease-indeterminate from childhood to adulthood: within a 25 year period. Clin Exp Gastroenterol. 6: 115—121. http://dx.doi.org/10.2147/CEG.S44700; PMid:23901288 PMCid:PMC3726299

42. Van Assche G, Dignass A, Panes JJ et al. 2010. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Crohns Colitis. 4: 17—27. http://dx.doi.org/10.1016/j.crohns.2009.12.003

43. Turner D, Griffiths AM. 2011. Acute severe ulcerative colitis in children: a systematic review. Inflamm Bowel Dis. 17: 440—449. http://dx.doi.org/10.1002/ibd.21383; PMid:20645317

44. Ulcerative colitis: management in adults, children and young people (NICE Clinical Guideline CG166). Arch Dis Child Educ Pract Ed. 2014. 99; 5: 194—197. Published Online First: 12 May 2014.